Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.07.2020 | Case report

Paclitaxel/pembrolizumab/temozolomide

Various toxicities: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Chen S, et al. Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports. Journal of Cancer Research and Therapeutics 16: 387-392, No. 2, Apr 2020. Available from: URL: http://doi.org/10.4103/jcrt.JCRT_75_20 Chen S, et al. Transcatheter arterial infusion of anti-programmed cell death 1 antibody pembrolizumab combined with temozolomide or nab-paclitaxel in patient with primary anorectal malignant melanoma: Four case reports. Journal of Cancer Research and Therapeutics 16: 387-392, No. 2, Apr 2020. Available from: URL: http://​doi.​org/​10.​4103/​jcrt.​JCRT_​75_​20
Metadaten
Titel
Paclitaxel/pembrolizumab/temozolomide
Various toxicities: 3 case reports
Publikationsdatum
01.07.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-80446-9

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Adalimumab

Case report

Dexamethasone

Case report

Pembrolizumab